Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Buy" by Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have earned an average rating of "Buy" from the ten research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $30.25.

RCUS has been the subject of several recent research reports. Bank of America lowered their price target on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. HC Wainwright raised shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $18.00 to $24.00 in a research note on Wednesday, February 26th. Finally, Morgan Stanley cut their target price on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th.

Insiders Place Their Bets

In related news, CEO Terry J. Rosen acquired 19,800 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were bought at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the acquisition, the chief executive officer now owns 2,554,160 shares in the company, valued at $26,001,348.80. This trade represents a 0.78 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Yasunori Kaneko bought 20,000 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were purchased at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the transaction, the director now owns 28,400 shares of the company's stock, valued at $285,704. This represents a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RCUS. Jane Street Group LLC raised its stake in shares of Arcus Biosciences by 59.8% in the 3rd quarter. Jane Street Group LLC now owns 217,041 shares of the company's stock valued at $3,319,000 after buying an additional 81,193 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Arcus Biosciences by 11.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company's stock valued at $8,669,000 after acquiring an additional 59,536 shares during the period. Barclays PLC raised its position in Arcus Biosciences by 49.0% in the third quarter. Barclays PLC now owns 118,693 shares of the company's stock worth $1,816,000 after purchasing an additional 39,015 shares in the last quarter. US Bancorp DE lifted its stake in Arcus Biosciences by 2,432.0% during the fourth quarter. US Bancorp DE now owns 6,887 shares of the company's stock worth $103,000 after purchasing an additional 6,615 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in Arcus Biosciences during the fourth quarter valued at approximately $207,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Arcus Biosciences Stock Up 7.8 %

Shares of NYSE RCUS traded up $0.59 during mid-day trading on Wednesday, reaching $8.09. The company had a trading volume of 1,197,078 shares, compared to its average volume of 776,518. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The company has a market capitalization of $850.04 million, a price-to-earnings ratio of -2.57 and a beta of 1.54. The stock has a fifty day moving average of $9.70 and a two-hundred day moving average of $13.59. Arcus Biosciences has a 12-month low of $6.50 and a 12-month high of $18.98.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. As a group, equities research analysts expect that Arcus Biosciences will post -3.15 EPS for the current year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.